Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Aberg

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|November 19, 2014
Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon inductionAvelino Teixeira, Benjamin Yen, Gabriele Luca Gusella, et al.
Annals of Internal Medicine|September 25, 2020
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines PanelAlice K Pau, Judith Aberg, Jason Baker, et al.
The Journal of Infectious Diseases|March 19, 2010
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz, Florin Vaida, C Bradley Hare, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2014
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapyJeffrey M Jacobson, Hongying Wang, Rebeka Bordi, et al.
Contemporary Clinical Trials Communications|November 9, 2019
Decreasing risk among HIV patients on opioid therapy for chronic pain: Development of the TOWER intervention for HIV care providersJessica Robinson-Papp, Judith Aberg, Emma K T Benn, et al.
Vaccine|November 15, 2025
Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIVMeenakshi M Rana, Brandy Haydel, Gina Carrara, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIVMeenakshi M Rana, Brandy Haydel, Gina Carrara, et al.
Science (New York, N.Y.)|October 29, 2020
Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsAnia Wajnberg, Fatima Amanat, Adolfo Firpo, et al.
The Lancet. Microbe|October 5, 2020
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational studyAnia Wajnberg, Mayce Mansour, Emily Leven, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|November 19, 2014
Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon inductionAvelino Teixeira, Benjamin Yen, Gabriele Luca Gusella, et al.
Annals of Internal Medicine|September 25, 2020
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines PanelAlice K Pau, Judith Aberg, Jason Baker, et al.
The Journal of Infectious Diseases|March 19, 2010
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz, Florin Vaida, C Bradley Hare, et al.
The New England Journal of Medicine|March 27, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionMichael Kozal, Judith Aberg, Gilles Pialoux, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2014
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapyJeffrey M Jacobson, Hongying Wang, Rebeka Bordi, et al.
Contemporary Clinical Trials Communications|November 9, 2019
Decreasing risk among HIV patients on opioid therapy for chronic pain: Development of the TOWER intervention for HIV care providersJessica Robinson-Papp, Judith Aberg, Emma K T Benn, et al.
Vaccine|November 15, 2025
Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIVMeenakshi M Rana, Brandy Haydel, Gina Carrara, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIVMeenakshi M Rana, Brandy Haydel, Gina Carrara, et al.
Science (New York, N.Y.)|October 29, 2020
Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsAnia Wajnberg, Fatima Amanat, Adolfo Firpo, et al.
The Lancet. Microbe|October 5, 2020
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational studyAnia Wajnberg, Mayce Mansour, Emily Leven, et al.
Pageof 5